Devonian Health Group Achieves Promising Breakthrough in Pulmonary Fibrosis Treatment Devonian Health Group showcases promising results from a study on Thykamine™, showing significant antifibrotic effects in pulmonary fibrosis models, outperforming traditional treatments.

Devonian Health Group Achieves Promising Breakthrough in Pulmonary Fibrosis Treatment #Canada #Quebec #Pulmonary_Fibrosis #Thykamine #Devonian

First Biomarker for Idiopathic Pulmonary Fibrosis Accepted by FDA, Promising More Efficient Treatments The PROLIFIC consortium's Risk Score has been accepted into the FDA Biomarker Qualification Program, paving the way for better treatments for idiopathic pulmonary fibrosis.

First Biomarker for Idiopathic Pulmonary Fibrosis Accepted by FDA, Promising More Efficient Treatments #United_States #Chicago #Pulmonary_Fibrosis #PROLIFIC_Risk_Score #FDA_CDER

FDA Grants Approval for JASCAYD® Tablets to Treat Progressive Pulmonary Fibrosis The U.S. FDA has approved JASCAYD® (nerandomilast) for treating progressive pulmonary fibrosis in adults, providing a new hope for patients with this severe condition.

FDA Grants Approval for JASCAYD® Tablets to Treat Progressive Pulmonary Fibrosis #United_States #Ridgefield #Pulmonary_Fibrosis #JASCAYD® #nerandomilast

AI-Driven e-Lung Technology by Brainomix Revolutionizes Diagnosis of Pulmonary Fibrosis A groundbreaking study reveals that Brainomix’s e-Lung technology significantly enhances the early detection of Progressive Pulmonary Fibrosis, improving patient outcomes.

AI-Driven e-Lung Technology by Brainomix Revolutionizes Diagnosis of Pulmonary Fibrosis #USA #Chicago #Brainomix #Pulmonary_Fibrosis #e-Lung

American Lung Association Introduces Free Educational Program for Pulmonary Fibrosis Awareness In recognition of Pulmonary Fibrosis Awareness Month, the American Lung Association unveils a new educational initiative aimed at supporting individuals living with this challenging lung disease.

American Lung Association Introduces Free Educational Program for Pulmonary Fibrosis Awareness #USA #American_Lung_Association #Chicago,_IL #Pulmonary_Fibrosis #Lung_Health_Navigators

The Importance of ILD Day: Raising Awareness for Lung Diseases in America Each September, ILD Day raises crucial awareness about interstitial lung diseases affecting over 250,000 Americans. The upcoming event will educate the public and connect experts.

The Importance of ILD Day: Raising Awareness for Lung Diseases in America #United_States #Chicago #Pulmonary_Fibrosis #ILD_Day #Lung_Diseases

Pulmonary Fibrosis Awareness Month: Raising Hope and Understanding Nationwide September marks Pulmonary Fibrosis Awareness Month, bringing national attention to the urgent need for awareness and support for patients affected by this life-threatening disease.

Pulmonary Fibrosis Awareness Month: Raising Hope and Understanding Nationwide #United_States #Chicago #Pulmonary_Fibrosis #PFF #Lung_Disease

¡Ya tenemos ganador de la Beca a la Innovación en EPID 2025! | Boehringer Ingelheim ¡Ya tenemos ganador de la Beca a la Innovación en EPID 2025! 🎉  Enhorabuena al Dr. Josep Mercader Barceló, Investigador del grupo Biología Molecular, Salud Geográfica y One Health (MolONE) de la Univ...

The objective of our project @Fibroair is to characterize the microbiota of the exhaled air in patients with pulmonary fibrosis #exhaled_air #microbiota #pulmonary_fibrosis
es.linkedin.com/posts/boehri...

Pulmonary Fibrosis Foundation Hosts PFF Walk 2025 to Unite and Inspire Change Join the Pulmonary Fibrosis Foundation for PFF Walk 2025, a special event celebrating community and raising funds for pulmonary fibrosis research and support.

Pulmonary Fibrosis Foundation Hosts PFF Walk 2025 to Unite and Inspire Change #United_States #Chicago #Research #Pulmonary_Fibrosis #PFF